November 1, 2022 – SK pharmteco, a global contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, today announced that Joerg Ahlgrimm will be appointed as the Chief Executive Officer. Ahlgrimm will assume the global leadership of the company and spearhead its next phase of innovation and global growth.
“On behalf of the entire Board, I am thrilled to welcome Joerg as the CEO at a pivotal moment as SK pharmteco strives to optimize manufacturing expertise and capture the opportunities in the global pharmaceutical industry,” said Dong-hyun Jang, Chairman of SK pharmteco’s Board of Directors and CEO of SK Inc. “With his solid track record of global operations and manufacturing in addition to his expertise in both small molecule and CGT business, Joerg is uniquely qualified in accomplishing the company’s key objectives in becoming the most trusted global partner for pharmaceutical clients,” he added.
Ahlgrimm brings more than 25 years of experience in global
operations, especially with his expertise in the pharmaceutical
industry. Most recently, he served as president and CEO of the Center of
Breakthrough Medicines (“CBM”) of the United States, in which SK
pharmteco is the second-largest shareholder.
“I am delighted to join forces with the SK pharmteco team to drive
further growth of the company,” said Ahlgrimm. “With the entrenched
capacities in small molecule and a new drive for CGT, SK pharmteco is in
an exciting stage of growth with a goal to become one of the world’s
leading CDMOs. I look forward to the immense opportunities lying ahead
with SK pharmteco’s continued capabilities and capacity expansion as
well as unparalleled customer service.”
Dr. Aslam Malik, has served as the CEO of AMPAC Fine Chemicals since
2005. His leadership was retained by SK Inc. when it acquired AMPAC Fine
Chemicals in 2018 and established SK pharmteco in 2019. “It has been an
honor to serve as CEO of SK pharmteco during this period of growth and I
would like to offer my sincere thanks to SK for the support. I strongly
believe Joerg will successfully lead SK pharmteco to its next phase of
growth,” said Dr. Malik.
Previously, Ahlgrimm served as the Head of Global Operations for
Pharma and Biotech at Lonza AG where he was responsible for 35 sites
across four continents. Prior to Lonza, he oversaw the manufacturing
network of 17 plants at Baxalta Inc., Baxter International’s bio-science
division, with network of more than 20 CMOs and the largest plasma
collection division in the industry.
Headquartered in Sacramento, California, SK pharmteco is a global
CDMO and a subsidiary of SK Inc., the strategic investment company for
SK Group, South Korea’s second-largest conglomerate. SK Group has
announced plans to invest billions of dollars in the U.S. across the
semiconductor, clean energy and life sciences industries. Under the
strategic initiative of SK Inc. to strengthen its CDMO business, SK
pharmteco was established in 2019 by consolidating highly complementary
CDMO business operations. SK pharmteco has established a well-balanced
business portfolio by engaging in small molecule & CGT to capture
both the robust and exponential growth of each market. Most recently, SK
pharmteco became the second-largest shareholder of CBM through its
investment in March 2022. Accordingly, it currently operates eight
global manufacturing sites in the United States, Europe, and South Korea
along with five R&D centers.
About SK pharmteco
SK pharmteco is the single customer-facing team comprised of SK
biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea, Yposkesi and most
recently The Center for Breakthrough Medicines. Creating substantial
market synergies in the API and Cell and Gene Therapy CDMO space by
combining highly complementary assets and expertise, this union enables
us to provide the highest-quality services to our customers.
With world-class state-of-the-art facilities and technology,
increased capabilities: energetic chemistry, continuous flow process,
controlled substances, particle engineering, high potency – with
world-class potent handling capability (down to low nanogram per cubic
meter levels). We have multiple cGMP manufacturing and development
sites, with ~1300m³ of capacity among 8 sites plus analytical services
facilities across USA, Korea and Ireland. For more information, visit skpharmteco.com.
SK Group, South Korea’s second-largest conglomerate, is a collection
of global industry-leading companies driving innovations in
semiconductors, sustainable energy, telecommunications and life
sciences. Based in Seoul, SK invests in building sustainable businesses
around the world with a shared commitment to reducing global greenhouse
gas emissions and increasing the use of renewable energy.
SK companies combined have more than $139 billion in global annual
revenue and employ more than 100,000 people worldwide. SK companies are
investing billions of dollars in expanding their U.S. presence with
business operations or partnerships in hydrogen energy and fuel cells,
EV battery manufacturing and technology, energy storage solutions,
pharmaceutical manufacturing, and development, semiconductors, and
advanced materials. For more information, visit sk.com.